In today’s episode, we spoke with Jennifer B. Valerin, MD, PhD. Dr Valerin is an assistant professor in the Divisions of Hematology and Oncology and Medicine at the University of California, Irvine School of Medicine.<br>In our exclusive interview, Dr Valerin discussed the clinical role of liposomal irinotecan (Onivyde) in pancreatic cancer management, factors influencing the decision to use liposomal irinotecan in practice, and developments she is excited to see as the pancreatic cancer landscape is shifting toward highly targeted and combination approaches.

Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD 

OncLive® On Air

Welcome to OncLive On Air. I'm your host today, Aisling Wehner. In today's episode, we spoke with Jennifer B. Valerin, MD, PhD. In our exclusive interview, Dr. Valerin discussed the clinical role of liposomal irinotecan in pancreatic cancer management, factors influencing the decision to use this agent in practice, and development she is excited to see as the pancreatic cancer landscape is shifting toward highly targeted and combination approaches.

S18 So speaking about the evolving treatment landscape with pancreatic cancer, what is the current role of liposomal irinotecan in the metastatic paradigm here?

Dr. liposomal irinotecan, there was two main sentinel trials looking at its use in metastatic disease. First, of course, was NAPOLI-1, which was where the combination therapy, which is considered Naliri, which is 5FU plus liposomal irinotecan, was compared actually initially to liposomal irinotecan alone, 120 milligrams per meter squared every three weeks, but then 5FU and lucavorin as a monotherapy arm.

And this was in patients who were previously treated with gemcitabine-based therapy, so at least in the second line. There, the primary endpoint was overall survival, and it showed median overall survival of 6.2 versus 4.2 months. And so there was definitely a survival benefit that was seen, but was not seen amongst the monotherapy arms.

And there, also, the other, I think, defining factor was the overall response rate, which was definitely improved in the combination therapy compared to monotherapy, as well as an improved disease control rate, which is the partial response and complete response as well as stable disease compared to those who have progression.

Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.